Posted by Michael Wonder on 30 Sep 2019
U.S. FDA approves Invokana (canagliflozin) to treat diabetic kidney disease and reduce the risk of hospitalisation for heart failure in patients with type 2 diabetes and diabetic kidney disease
30 September 2019 - Approval is based on the landmark Phase 3 CREDENCE renal outcomes study - the only completed renal outcomes study of a diabetes medicine.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. FDA approved a new indication for Invokana (canagliflozin) to reduce the risk of end-stage kidney disease (ESKD), worsening of kidney function, cardiovascular death, and hospitalisation for heart failure in adults with type 2 diabetes and diabetic kidney disease (nephropathy) with a certain amount of protein in the urine.
Invokana is now the only type 2 diabetes medicine indicated to both treat diabetic kidney disease and reduce the risk of hospitalisation for heart failure in patients with type 2 diabetes mellitus an diabetic kidney disease.
